Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence.

Journal Article (Clinical Trial;Journal Article)

OBJECTIVE: To examine the efficacy of atypical neuroleptics for decreasing craving and drug relapses during protracted withdrawal in individuals dually diagnosed with schizophrenia and cocaine dependence. METHOD: We conducted a 6-week, open-label pilot study comparing risperidone with typical neuroleptics in a sample of withdrawn cocaine-dependent schizophrenia patients. RESULTS: Preliminary results suggest that individuals treated with risperidone had significantly less cue-elicited craving and substance abuse relapses at study completion. Further, they showed a trend toward a greater reduction in negative and global symptoms of schizophrenia. CONCLUSION: Atypical neuroleptics may help reduce craving and relapses in this population. Future research should include more rigorous double-blind placebo-controlled studies with this class of medications.

Full Text

Duke Authors

Cited Authors

  • Smelson, DA; Losonczy, MF; Davis, CW; Kaune, M; Williams, J; Ziedonis, D

Published Date

  • September 2002

Published In

Volume / Issue

  • 47 / 7

Start / End Page

  • 671 - 675

PubMed ID

  • 12355680

International Standard Serial Number (ISSN)

  • 0706-7437

Digital Object Identifier (DOI)

  • 10.1177/070674370204700710


  • eng

Conference Location

  • United States